Royalty Pharma Considers Sweetened Deal for Elan

12.04.2013 - U.S. investment firm Royalty Pharma is considering sweetening its $6.6 billion offer for Irish drugmaker Elan by paying Elan shareholders more if the multiple sclerosis drug...